AstraZeneca braces for further PLATO headaches
This article was originally published in Scrip
AstraZeneca is downplaying concerns over the US Department of Justice's decision to investigate PLATO, the huge pivotal clinical trial that formed the basis of the approval of the anti-clotting drug ticagrelor (Brilinta/Brilique).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.